It’s a day of reckoning for marijuana and psychedelics research! The Drug Enforcement Administration (DEA) has released new production quotas for marijuana and certain psychedelics to facilitate more research on the Schedule I drugs. This marks an important milestone in the advancement of understanding the medicinal benefits these substances can offer. The changes to the quota system set the stage for more studies on marijuana’s therapeutic potential, as well as the therapeutic applications of psychedelics, such as psilocybin, ayahuasca, and dimethyltryptamine, for treating mental health disorders.
The announcement is seen as a major step forward in the implementation of the Department of Justice’s new drug policy. The DEA also stated that it will prioritize the registration of entities to produce psychedelics for research purposes. This news is sure to have wide-reaching implications for the medical and scientific community, as well as for many patients who could benefit from these substances for medical treatment.
The Main Takeaways:
• The Drug Enforcement Agency (DEA) has issued an increase in marijuana and psychedelics research production quota amounts for 2021.
• The new quota will be more than double the amount of production quotas from 2020.
• This move by the DEA is intended to increase the amount of research into the benefits of these substances.
• For marijuana, the increased quota will allow the DEA to provide an additional 9,500 kilograms of material for research.
• For psychedelics, production quotas for compounds such as MDMA, psilocybin and DMT have also been increased.
• The DEA has noted that this will help to facilitate necessary research into the potential benefits, risks and side effects of these substances for therapeutic and medical usage